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Abstract
Lifetime prevalence estimates of psychotropic medicine use as well as preva-
lence of DSM-IV prescription drug use disorders from the baseline investiga-
tion of the Early Developmental Stages of Psychopathology (EDSP) Study are
presented. Use of prescription medication at some time in their life was
reported by 27.4% of the respondents. Illicit use of prescription drugs, which
means an intake without medical legitimation, was reported by 4.5% of the
sample. The findings suggest that abuse of and dependence on prescription
drugs, with most cases reporting polysubstance use, is quite rare in the 14- to
24-year-olds. DSM-IV abuse was more prevalent than dependence (0.5 vs.
0.3%). In general, women reported higher prevalence rates of prescription
drug use, whereas men reported higher prevalence rates of prescription drug
disorders. This result suggests that men have a higher risk to develop a sub-
stance-use-related disorder.
OOOOOOOOOOOOOOOOOOOOOO
Introduction
Knowledge about the use of prescription drugs among
adolescents and young adults is sparse, with considerable
variation among the few studies available. Moreover, no
recent study is available evaluating the abuse and depen-
dence of prescription drugs according to international
diagnostic criteria such as ICD-10 [1] and DSM-IV [2].
These criteria define substance dependence as a cluster of
physiological, cognitive and behavioral symptoms indi-
cating that the subject continues to use a substance
despite knowing about substance-related problems. Sub-
stance abuse is defined as a maladaptive pattern of sub-
stance use manifested by recurrent and adverse conse-
quences (e.g. legal problems, recurrent social and interper-
sonal problems) related to repeated use of the substance.
Our current knowledge about the use of psychotropic
medicines in Germany comes mainly from four sources:
(a) the Munich and Lübeck Blood Pressure Study [3];
(b) the Upper Bavarian Field Study [4, 5]; (c) the repre-
sentative surveys (questionnaire and telephone) of drug
use commissioned by the Federal Ministry of Health in
1994 and 1995 [6, 7] and (d) a representative question-
naire survey by the Federal Ministry of Health in 1990
[8]. The studies differ considerably in terms of sampling
and assessment instruments, the time frame used (cur-
rent, lifetime), the classifications of psychoactive sub-
stances, as well as the analysis used, making it difficult to
compare the results directly.
The EDSP study is supported by the German Federal Ministry for
Research and Technology, project No. 01EB94056.
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In the Munich Blood Pressure Study (MBS, 1981) and
the Lübeck Blood Pressure Study (LBS, 1984) [3], 9.3% of
a representative sample of 20- to 69-year-old residents of
Munich (Lübeck: 7.0%) reported having taken some type
of psychotropic medication (including hypnotics) during
the preceding 7 days. However, it is not clear whether
these substances had been prescribed by a doctor or
whether they were used appropriately as prescribed. Simi-
lar findings were reported from the first wave (1975–
1979) of the Upper Bavarian Study (1,536 persons aged
15 years and older), in which 8.1% of the respondents
reported the use of psychotropic medications (e.g. tran-
quilizers, antidepressants, neuroleptics, stimulants, and
other drugs acting on the CNS) during the week prior to
the interview [5]; no differentiation between licit and il-
licit use was made. The 1-week prevalence use rate was
about three times higher in women (11.4%) compared to
men (4.1%). For the youngest age group (15–24 years), a
1-week prevalence of use of 0.8% was estimated. In the
second wave of this study (conducted between 1980 and
1983), the rates were considerably higher with reported
use of psychotropic medications (not including hypnotics
and sedatives) by 18.1% of the sample in the 4 weeks pre-
ceding the assessment. Additionally, 16.9% used analge-
sic drugs and 4.8% hypnotics or sedatives during this peri-
od [9]. Again, women consistently showed higher rates of
use for most psychotropic drugs.
Whereas the above studies were based on clinical and
personal assessments, the survey conducted by the Feder-
al Ministry of Health [6] in 1994 was based on a telephone
survey among a representative sample of 18- to 59-year-
old residents. More than 10% (12.2%) of this sample
reported taking psychotropic medicines (pain relievers,
sleeping pills, sedatives, stimulants, appetite suppres-
sants) with a frequency of at least once a week in the pre-
vious month. Women reported higher prevalences of psy-
chotropic medicine use than men (15.2 vs. 9.4%). Con-
sumption of these drugs increased with age: the lowest
rates were found for the 18- to 20-year-olds (7.8%) and 25-
to 29-year-olds (7.3%), whereas the highest rates were
found at age 40 years and older (114%). In the question-
naire survey [7] 1 year later, slightly higher rates of 16%
(women 19.3%, men 12.8%) were reported by the respon-
dents (age group 18–20 years: 9.9%; above 40 years:
116%).
Concerning adolescents and young adults, the results
of the representative questionnaire survey of 1990 [8]
should be mentioned. Based on 18,854 subjects aged 12–
39 years in West Germany and 2,420 age-matched sub-
jects in East Germany, this study found that 0.3–2.4% of
the 12- to 24-year-olds took analgesics, sleeping pills, tran-
quilizers or other psychotropic substances without pre-
scription at least once a week. In particular, rates of seda-
tives and analgesics/opioids use were higher in women.
In addition to the cited surveys, some data about drug
use in specific German Länder are available [10, 11]. The
results of Nordlohne et al. [11], comparing 1-year preva-
lence rates for medication use in 14- to 16-year-old adoles-
cents of Saxony (n = 1,972) and Northrhine-Westfalia (n =
1,695) show that in this age group 1.7% of the respondents
(East: 0.8%) used sedating and 1.0% (East: 1.4) stimulat-
ing drugs at least once a week in the year preceding the
survey.
There are only two German epidemiological studies
available that provide at least some limited data on the
prevalence of prescription drug-related substance abuse
and dependence in adults as assessed by clinical psychia-
trists. Based on DSM-III criteria, Fichter [9] estimated a
5-year prevalence of 0.07% for barbiturate abuse, 0.33%
for other hypnotic-related abuse diagnoses with 0.07% of
the sample fulfilling DSM-III criteria for opioid-related
substance abuse during the preceding 5 years among resi-
dents of the Upper Bavarian area of Traunstein. In the
Munich Follow-up Study (MFS) [12], a national represen-
tative survey of 25- to 65-year-olds, 1.79% of the respon-
dents (exclusively women) met criteria for medication-
related substance use disorders (abuse or dependence)
according to DIS/DSM-III criteria.
In summary, there are only few epidemiological data
about the use of prescription drugs among adolescents
and young adults in Germany and even fewer about abuse
and dependence with almost no data about the frequency
of medication-related substance use disorders.
This article reports prevalence data on the use of pre-
scription drugs, their illicit (unprescribed) use as well as
clinically manifest diagnoses of abuse and dependence
according to DSM-IV among German adolescents and
young adults. The term psychotropic prescription drugs
includes substances that are usually available as medi-
cines by prescription, e.g. stimulants, sedatives and pre-
scription analgesics or opioids. Illicit use of psychoactive
medication means a prolonged self-administration of sub-
stances that are taken for no legitimate medical purpose
or, if a medical condition is present, that are used in
amounts greater than that required for treatment. Follow-
ing the DSM-IV definition of opioid-related substance use
disorders, we will evaluate prescription drug-related
abuse and dependence only for subjects with illicit use of
prescription drugs.
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Table 1. Prescription drugs covered by the M-CIDI
Drug classes Examples
Amphetamines/
stimulants
AN1, Captagon, Katovit N, Reactivan, Ritalin,
Tradon, Fugoa, Ponderax, Recatol, Rosmon
Sedatives/
hypnotics/
anxiolytics
Adumbran, Calmonal, Dalmadorm, Diazepam,
Halzion, Lexotanil, Librium, Medinox,
Mogadan, Noctamid, Normoc, Planum,
Rohypnol, Tafil, Tranxilium, Valium, Vesparax
Opioids/
analgesics
Codeine, Codicaps, Codipront, Paracodin,
Tussoretard, Dolomo, L-Polamidon, Valoron,
MST, Nedolon, Remedacen, Temgesic, Develin,
Tramal, Dolviran
The following specific questions will be addressed:
(1) How frequently do 14- to 24-year-olds report the
use of any psychotropic drug?
(2) How frequently are these drugs used without pre-
scription, either to feel better, to relax or to otherwise
modify mood?
(3) How prevalent is DSM-IV abuse of and depen-
dence on psychotropic drugs among 14- to 24-year-old
German adolescents and young adults?
Further age- and gender-specific differences as well as
the most frequent criteria for abuse and dependence will
be explored.
Methods
A complete and detailed description of design, sample, instru-
ments, procedures and statistical methods are given in Wittchen et
al. [this issue].
Assessment of Use of Prescription Drugs
In the assessment of prescription drugs [for a detailed overview of
the substance use sections of the M-CIDI see Wittchen et al., this
issue], we first presented a list of the most often prescribed market
names for (a) amphetamines/stimulants; (b) sedatives, hypnotics and
anxiolytics, and (c) prescription analgesics and opioids. Table 1
shows the visually presented response list with examples for each
type of substance. The names of this list were taken from local statis-
tics to represent the most frequently marketed medications. How-
ever, the respondent was free to add any other substance that was
then properly grouped later in the editing process after the inter-
view.
The subjects were asked if they had ever been prescribed any of the
listed drugs. If yes, they were asked first, to mark those drugs in the
list that they had taken every day for at least 2 weeks and second, to
name all prescription drugs they had used in larger amounts or for a
longer period than was prescribed. With these questions we intended
to assess if a subject deviated from prescription regimen. In a second
step, we asked the subject if he or she had ever used any of the listed
substances on its own, without prescription, either to relax, feel bet-
ter, feel high or feel more active or alert. If yes, the substance was
marked and the subject was asked about the frequency of use. Here
our intention was to assess the use of psychotropic drugs without pre-
scription. ‘Regular users’ were defined as subjects with use of pre-
scription drugs in greater amounts than prescribed or without pre-
scription on at least five occasions. We subsequently evaluated
(a) stimulants, (b) sedatives, and (c) opioids/analgesics for quantity
and frequency as well as the DSM-IV criteria for substance abuse and
substance dependence by type of substance for the regular users.
Results
Prevalence of Prescription Drug Use
The upper portion of table 2 reports the lifetime esti-
mates for prescription drug use for 14- to 24-year-olds by
gender and age groups. More than a quarter (27.4%) of all
respondents reported having used a prescription drug
either with or without prescription at least once. The vast
majority (23.5%) indicated having taken these drugs only
by prescription. The rate for those reporting having taken
psychoactive medications with and without prescription
was 2.4%, whereas prevalence of using prescription drugs
without any prescription was 1.5%.
Women were more likely than men to use prescription
drugs (31.2 vs. 23.5%; OR: 1.5; 95% Cl: 1.25–1.73). They
were also more likely to get a psychotropic substance pre-
scribed (29.3 vs. 22.4%; OR: 1.4; 95% CI: 1.22–1.69; p !
0.001) and to take psychotropic substances without pre-
scription more often than men, either to feel better or to
relax (4.6 vs. 3.2%; OR: 1.5; 95% CI: 0.99–2.12; p !
0.05).
Prevalence of use increases tremendously with age. For
the older age group (18–24 years) the rates are at least
twice as high as in the younger age group (any use: OR:
3.1; 95% CI: 2.52–3.82; only prescribed: OR: 2.6; 95% CI:
2.08–3.19; only unprescribed: OR: 5.0; 95% CI: 1.71–
14.58; both: OR: 10.4; 95% CI: 3.26–33.03). Differences
between the age groups are especially pronounced in
women (any use: OR: 3.6; 95% CI: 2.72–4.85; only pre-
scribed: OR: 3.1; 95% CI: 2.30–4.18; only unprescribed:
OR: 4.3; 95% CI: 1.21–15.53; both: OR: 5.9; 95% CI:
1.69–17.89).
The lower portion of table 2 shows that only a few sub-
jects (2.6%) reported continuous use of prescription drugs
over a period of 2 weeks or longer. An intake of prescrip-
tion drugs for a period of at least 2 weeks combined with
an intake on at least five occasions without prescription
was reported by 0.4% of the respondents with 1.3%
reporting that they had taken psychotropic drugs without
prescription at least five times.
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Table 2. Lifetime exposure to prescription drugs and frequency of intake in 14- to 24-year-olds (%, weighted)
Total
total
%w Nw
14–17 yrs
%w Nw
18–24 yrs
%w Nw
Male
total
%w Nw
14–17 yrs
%w Nw
18–24 yrs
%w Nw
Female
total
%w Nw
14–17 yrs
%w Nw
18–24 yrs
%w Nw
Ever use of medications
Any use (lifetime) 27.4 826 13.8 127 33.3 699 23.5 350 13.1 61 28.1 289 31.2 476 14.6 66 38.2 410
Only use with prescription 23.5 709 13.1 121 28.1 590 20.3 303 12.9 60 23.6 243 26.7 408 13.3 61 32.4 347
Use without precription 1.5 45 0.4 4 2.0 41 1.1 16 0.2 1 1.5 15 1.9 29 0.6 3 2.4 26
Prescribed and nonprescribed use 2.4 72 0.3 3 3.3 69 2.1 31 – – 3.1 31 2.7 41 0.7 3 3.5 38
Frequency
Prescribed daily 1 2 weeks 2.6 79 1.2 11 3.2 68 2.4 35 1.2 5 2.9 30 2.9 44 1.2 6 3.6 38
Prescribed daily 12 weeks and
nonprescribed 5+ 0.4 13 0.1 0 0.6 12 0.6 8 – – 0.8 8 0.3 4 0.1 0 0.4 4
Only nonprescribed 5+ 1.3 39 0.2 2 1.7 37 1.0 15 – – 1.5 15 1.5 23 0.4 2 2.0 21
Nw = Weighted number of respondents; %w = weighted percentage; total Nw = 3,021; total 14–17: Nw = 921; total 18–24: Nw = 2,100;
male Nw = 1,493; male 14–17: Nw = 464; male 18–24: Nw = 1,029; female Nw = 1,528; female 14–17: 457; female 18–24: Nw = 1,072.
Table 3. Illicit use of prescription drugs in 14- to 24-year-olds (%, weighted)
Total
total
%w Nw
14–17 yrs
%w Nw
18–24 yrs
%w Nw
Male
total
%w Nw
14–17 yrs
%w Nw
18–24 yrs
%w Nw
Female
total
%w Nw
14–17 yrs
%w Nw
18–24 yrs
%w Nw
Illicit use of prescription drugs
Ever 4.5 134 1.1 11 5.8 124 3.8 56 0.8 4 5.1 52 5.0 78 1.4 7 6.6 72
Use in larger amounts than prescribed 0.6 17 0.4 4 0.6 14 0.6 9 0.6 3 0.6 6 0.5 8 0.2 1 0.7 8
Use without prescription 3.6 108 0.7 7 4.8 101 2.8 42 0.2 1 4.0 41 4.3 66 1.2 6 5.6 60
Both 0.3 9 – – 0.4 9 0.4 5 – – 0.5 5 0.2 4 – – 0.3 4
Regular illicit use of prescription drugs1
Ever 2.4 71 0.7 6 3.1 65 2.2 33 0.6 3 2.9 30 2.5 39 0.7 3 3.3 36
Larger amounts than prescribed 0.7 20 0.4 4 0.8 16 0.6 9 0.6 3 0.6 6 0.7 11 0.2 1 1.0 10
Without prescription 1.5 45 0.3 3 2.0 43 1.2 18 – – 1.8 18 1.7 27 0.5 3 2.3 24
Both 0.2 6 – – 0.3 6 0.4 5 – – 0.5 5 0.1 1 – – 0.1 1
Regular use: specific substances
Stimulants 0.8 24 0.3 3 1.0 22 0.7 10 – – 1.0 10 0.9 14 0.5 3 1.1 12
Sedatives 0.7 21 0.1 0 1.0 21 0.9 13 – – 1.3 13 0.5 8 0.1 0 0.7 7
Opioids/analgesics 1.4 42 0.4 3 1.8 38 1.4 21 0.6 3 1.8 18 1.3 20 0.1 0 1.9 20
Nw = Weighted number of respondents; %w = weighted percentage.
1 Regular use = use in larger amounts than prescribed or at least five times unprescribed.
Respondents aged 18–24 years answered these ques-
tions in the affirmative much more frequently than 14- to
17-year-olds. Unlike the findings in the rates of use, how-
ever, there are no clear gender differences, the frequency
of intake being comparable between men and women.
Illicit Use of Prescription Drugs
In our study illicit use of prescription drugs was
defined as use of psychoactive medications without medi-
cal legitimation, that is, the subject took more than was
prescribed or used drugs prescribed for someone else.
Overall, 4.5% of the sample reported having used pre-
scription drugs without medical legitimation at some time
(table 3). Analysis of age differences shows that preva-
lences of 18- to 24-year-olds are five times higher than
those found for the younger age group (5.8 vs. 1.1%; OR:
5.5; 95% CI: 3.07–11.53; p ! 0.001). Women revealed
higher prevalence rates than men (5.0 vs. 3.8%; OR: 1.4;
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Fig. 1. Lifetime prevalence rates of substance use disorders related to prescription drugs in 14- to 24-year-old
German adolescents and young adults.
95% CI: 0.96–1.92; p ! 0.08), although the results were
only marginally significant. The dominant pattern of illic-
it use of prescription medication is the use of psychoac-
tive drugs that had never been prescribed: 80% (preva-
lence: 3.9%) of all illicit users had taken medications that
had not been prescribed for any medical indication.
The lifetime prevalence of regular illicit use was 2.4%
with no noticeable gender difference (men: 2.2%, women:
2.5%). Comparable to the other use findings, the preva-
lence rates of the older age group are much higher than
those of the younger age group (regular illicit use: OR: 5.4;
95% CI: 2.24–13.05), especially pronounced for regular
use with and without prescription (reported only by sub-
jects older than 17 years). Among regular users, more than
half used the drug without prescription. Most frequently
mentioned types of substances were analgesics and
opioids (1.4%) followed by stimulants (0.8%) and seda-
tives (0.7%).
In the period of heaviest use, about 50% of all regular
users reported having used the substance on at least 3–4
days a week.
Lifetime Prevalence of Substance Use Disorders due to
Illicit Use of Prescription Drugs
Figure 1 summarizes the lifetime prevalences of sub-
stance use disorders related to prescription drugs by gen-
der, age and type of substance.
The figure reveals four major findings:
(1) Substance disorders are only prevalent among the
18- to 24-year-olds, only one person in the younger age
group met the criteria for psychotropic medication-relat-
ed substance use disorder (amphetamine dependence);
(2) although women take medication much more fre-
quently, only very few go on to develop a disorder;
(3) without regard of one case all subjects with a spe-
cific dependence diagnosis met also abuse criteria for the
substance, and
(4) the rates for men are almost three times higher than
those for women, especially for abuse.
Prevalence of Specific Diagnostic Criteria
Table 4 shows the distribution of DSM-IV substance use
dependence and abuse criteria among regular users as well
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Table 4. Distribution of DSM-IV dependence and abuse criteria (%) among regular users with and without diagnoses
DSM-IV criteria Frequency (%) of criteria
amphetamines
all regular
users
Nw = 24
regular users
with diagnosis
Nw = 7
sedatives/hypnotics/
anxiolytics
all regular
users
Nw = 21
regular users
with diagnosis
Nw = 9
analgesics/opiods
all regular
users
Nw = 42
regular users
with diagnosis
Nw = 8
Dependence
Tolerance 21.6 75.3 26.3 59.8 23.0 100.0
Withdrawal 33.4 75.3 41.7 51.0 25.0 77.8
Compulsive use 12.8 44.5 17.0 38.6 9.5 50.3
Unsuccessful desire to stop/cut down/control 9.0 31.5 22.5 51.0 14.6 77.8
Great deal of time using/
recovering from drug 19.7 68.5 36.2 71.2 16.8 77.8
Narrowing of repertoire 21.6 75.3 18.2 41.4 17.2 77.8
Continued use despite physical/psychological problems 19.9 69.2 27.1 61.5 14.6 77.8
Abuse
Failure in major role obligations 12.8 44.5 17.0 38.6 5.7 30.5
Recurrent use in hazardous situations 23.1 80.3 26.3 59.8 15.1 80.2
Recurrent legal problems 7.1 24.7 – – 14.6 77.8
Continued use despite persistent social problems 10.8 37.7 31.7 72.0 6.8 35.9
Nw = Weighted number.
as those with a diagnosis for each substance group. Among
the regular users without a diagnosis an unexpectedly high
number of subjects acknowledged the presence of depen-
dence symptoms. Among stimulant and analgesic/opioid
users withdrawal and tolerance were among the most fre-
quently mentioned symptoms, whereas sedative users most
often reported, besides withdrawal symptoms, a great deal
of time spent to use the drug or recover from its effects. For
those with substance use disorder there are remarkable dif-
ferences between the three substance groups. The highest
number of endorsed dependence symptoms is found for
those with an analgesic- and opioid-related disorder, fol-
lowed by those with an amphetamine-related disorder,
whereas sedative users with diagnosis report considerably
fewer symptoms. Among amphetamine and analgesic/
opioid users with diagnosis, tolerance and withdrawal are
the most frequently mentioned symptoms. In contrast to
these findings, continued use of the drug despite having
problems and the use of much time taking the drug or recov-
ering from its effects are the symptoms most often reported
by sedative users with diagnosis.
Similarily for abusers, quite different profiles were
found for each substance. Regarding the specific abuse
criteria, recurrent use in hazardous situations is a domi-
nant abuse symptom in amphetamine and analgesic/
opioid users with and without diagnosis. In contrast to
these findings, sedative users most often report continued
substance use despite persistent social problems caused
by the substance.
Discussion
Using data from our baseline investigation, the objec-
tives of this paper were first to examine the prevalence of
licit and illicit use of prescription drugs among adoles-
cents and young adults. Furthermore, the prevalence of
DSM-IV substance use disorders related to psychotropic
drugs was estimated.
Unlike previous representative surveys that used ques-
tionnaires with unknown psychometric properties the
presented findings are based on standardized personal
diagnostic interviews (M-CIDI) with proven reliability
[see Lachner et al. and Wittchen et al., this issue].
Before discussing our findings some critical issues need
to be addressed:
(1) The base rates for prescription drug abuse and
dependence were too low to provide reasonably stable
prevalence estimates, particulary among 14- to 17-year-
olds.
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(2) Even with the high response rate of 71% [Wittchen
et al., this issue], the findings could be influenced by non-
response. As results of other surveys (NCS, Kessler et al.
[13]; ECA, Eaton et al. [14]) have shown, higher psycho-
pathology is found among nonrespondents. The higher
nonresponse rate among 18- to 24-year-old women
[Wittchen et al., this issue] could have had an influence on
our findings. However, because no data for nonrespon-
dents are available at the moment we are not able to
examine the effect on our data in more detail.
(3) The M-CIDI does not allow the detailed determina-
tion which of the symptoms might be entirely due to pre-
scription drugs or the illicit drugs. Thus, the presented
prevalence of prescription drug abuse and dependence
should be interpreted as an upper bound estimates.
(4) The findings exclusively refer to adolescents and
young adults in the metropolitan area of Munich. Thus,
the prevalence rates cannot be used to estimate the size of
the problem for Germany as a whole. It might be possible
that prevalence rates from other metropolitan cities are
higher, whereas rates from more rural areas might be con-
siderably lower.
Despite these limitations, our study revealed three
important findings.
(1) In accordance with almost all studies available [see
review Perkonigg et al., this issue; 15], we confirm that
consumption rates of all types of the examined prescrip-
tion drugs are higher in women than in men, with 31.2%
of all women and 23.5% of all men reported having ever
used any prescription drugs. This pattern was quite stable
across all age groups and was also found for infrequent
and regular use.
The findings for the illicit use of prescription drugs,
however, tell a slightly different story. Regular illicit use,
defined as ‘use of prescription drugs in larger amounts or
more frequently than prescribed or without prescription,
either to feel better, feel high or to relax, on at least five
occasions’, was almost equally frequent among men
(2.2%) and women (2.5%), with no difference between
type of substances. The most frequently regularly used
prescription drugs were analgesics and opioids, followed
by stimulants (slightly higher in women), and sedatives
(slightly higher in men).
(2) Although women have considerably higher con-
sumption rates, male adolescents and adults are almost
three times more likely to develop a DSM-IV prescription
substance use disorder than women (men: 0.8%; women:
0.3%). To our knowledge, this finding has not been
reported previously. A closer case by case examination of
all cases revealed that all men with a prescription drug-
related abuse or dependence diagnosis also have at least
one additional disorder of another type of substance, most
frequently of alcohol, cannabis, stimulants and halluci-
nogens. By contrast, none of the women with a prescrip-
tion drug disorder fulfilled criteria for abuse or depen-
dence of any other illicit drug. This suggests: (a) that pre-
scription drug disorders in men, unlike to women, rarely
occur in pure forms and are usually associated with poly-
substance use and disorders, and (b) that there might exist
considerably different sex-specific pathways into abuse or
dependence.
(3) The examination of symptom profiles for depen-
dence revealed substance specific differences for regular
users as well as respondents with an abuse or dependence
diagnosis. The interpretation of this finding that possibly
reflects partly the different pharmacological effects of the
substances as well as associated consumption habits, how-
ever, is not clear, due to the above-mentioned limitations
of the assessment strategy which does not allow a proper
delineation of symptoms and criteria that are specifically
due to prescription drugs and those due to the regular use
of other illicit substances. As mentioned above, the low
base rates for estimating prevalences do not allow any fur-
ther exploration.
To conclude, our results indicate that illicit use of ‘legal
drugs’ occurs among adolescents and young adults almost
as frequently as the use of illicit drugs (not including can-
nabis; Perkonigg et al. [16], in this issue).
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